[{"question_number":"2","question":"A patient came with a 1-month history of fever, headache, and personality changes. Brain magnetic resonance imaging (MRI) shows bilateral cortical/subcortical hypodensities involving frontal, parietal, and occipital lobes. cerebrospinal fluid (CSF) analysis shows elevated protein. Which diagnosis can be demonstrated by T2 lesions in at least two areas of the central nervous system (CNS)?","options":["Multiple sclerosis","Bacterial meningitis","Viral meningitis","Neurosyphilis"],"correct_answer":"A","correct_answer_text":"Multiple sclerosis","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is A: Multiple sclerosis. According to the 2017 revisions of the McDonald criteria (Thompson et al., 2018), dissemination in space can be demonstrated by one or more T2-hyperintense lesions in at least two of four characteristic CNS regions (periventricular, juxtacortical, infratentorial, and spinal cord). The question\u2019s requirement of T2 lesions in at least two areas of the CNS directly reflects this dissemination-in-space criterion. Bacterial meningitis (Option B) presents with leptomeningeal enhancement, purulent CSF, and clinical signs of acute meningeal irritation, not multifocal parenchymal T2 lesions. Viral meningitis (Option C) similarly produces diffuse meningeal enhancement and lymphocytic pleocytosis but lacks focal T2-hyperintense demyelinating lesions. Neurosyphilis (Option D) may cause meningovascular inflammation and infarcts, but it does not meet the specific MRI criterion of T2 lesions in multiple CNS regions required for MS diagnosis. Thus, only MS satisfies the described imaging finding.","conceptual_foundation":"Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system characterized by perivenular inflammatory infiltrates, focal demyelination, and axonal injury. It is classified in ICD-11 under 8A40.0 (relapsing-remitting MS) and related codes for progressive forms. The McDonald criteria integrate clinical attacks, MRI findings, and CSF analysis to establish dissemination in time and space. Dissemination in space is evidenced by T2-hyperintense lesions in at least two of four typical regions: periventricular, juxtacortical, infratentorial, and spinal cord. A single clinical attack with MRI and CSF oligoclonal bands can suffice for diagnosis (Thompson et al., 2018). Differential diagnoses include acute disseminated encephalomyelitis, neuromyelitis optica spectrum disorder, CNS vasculitis, and viral encephalitis. Historically, Charcot first described MS in 1868, and MRI criteria have evolved through the Barkhof and McDonald revisions to improve sensitivity and specificity.","pathophysiology":"Normal CNS myelin insulates axons to facilitate saltatory conduction. In MS, autoreactive CD4+ T lymphocytes cross a disrupted blood\u2013brain barrier, recognize myelin antigens (e.g., myelin basic protein), and initiate an inflammatory cascade. Activated microglia and macrophages release cytokines (IL-17, IFN-\u03b3) and reactive oxygen species, leading to myelin and oligodendrocyte injury. Demyelinated axons show slowed conduction or conduction block, manifesting as neurological deficits. Chronic plaques show astrogliosis and axonal transection. Conformational MRI changes: acute inflammatory lesions are T2-hyperintense with gadolinium enhancement reflecting BBB breakdown; chronic lesions lose enhancement and may become T1-hypointense \u201cblack holes\u201d indicating axonal loss (Reich et al., 2018).","clinical_manifestation":"MS typically presents between ages 20\u201340, with a female-to-male ratio of approximately 3:1. Relapsing-remitting MS (RRMS) accounts for ~85% of initial presentations. Common symptoms include optic neuritis (20\u201330%), internuclear ophthalmoplegia, transverse myelitis, brainstem syndromes (e.g., facial numbness, diplopia), cerebellar signs (ataxia), and sensory disturbances (paresthesias). Cognitive impairment and fatigue occur in 40\u201360% of patients. Heat sensitivity (Uhthoff\u2019s phenomenon) and Lhermitte\u2019s sign may be present. Symptom onset is subacute over hours to days, with partial or full recovery over weeks to months.","diagnostic_approach":"First-tier evaluation includes MRI of brain and spinal cord with and without gadolinium, seeking dissemination in space and time per 2017 McDonald criteria (Level A evidence). Brain MRI sensitivity for MS lesions is ~95%; specificity ~80%. CSF analysis reveals oligoclonal IgG bands in 85\u201395% of patients (sensitivity 88%, specificity 86%). Evoked potentials (visual, somatosensory) show conduction delays. Differential workup includes infectious serologies, B12 levels, ANA, and aquaporin-4 antibodies. Pre-test probability is high in young adults with typical symptoms; post-test probability increases with positive MRI findings and CSF oligoclonal bands.","management_principles":"Acute relapses: high-dose IV methylprednisolone (1 g/day for 3\u20135 days; Class I, Level A). DMTs for RRMS include interferon-beta, glatiramer acetate, dimethyl fumarate, fingolimod, and monoclonal antibodies (natalizumab, ocrelizumab). The choice depends on disease activity and risk factors. Fingolimod reduces annualized relapse rate by ~50% (hazard ratio 0.45; 95% CI 0.35\u20130.59). Natalizumab demonstrates a 68% relative risk reduction (Rudick et al., 2010). Risk monitoring includes JCV index for natalizumab PML risk and lymphocyte counts for fingolimod.","follow_up_guidelines":"Neurological exams every 3\u20136 months; brain MRI annually or with suspected clinical activity. Monitor for new/enlarging T2 lesions and gadolinium-enhancing lesions. Laboratory monitoring per DMT: complete blood count, liver function tests, and JCV index as indicated. Rehabilitation includes physiotherapy for spasticity and gait training. Preventive measures: vaccination updates and vitamin D optimization.","clinical_pearls":"1. MRI dissemination in space: lesions in \u22652 of 4 regions (periventricular, juxtacortical, infratentorial, spinal). 2. Oligoclonal bands in CSF support MS diagnosis when MRI is equivocal. 3. Uhthoff\u2019s phenomenon: transient worsening of symptoms with heat exposure. 4. Natalizumab requires JCV index monitoring to mitigate PML risk. 5. Lhermitte\u2019s sign (electric shock sensation on neck flexion) suggests cervical cord involvement.","references":"1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. DOI:10.1016/S1474-4422(17)30470-2\n2. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169-180. DOI:10.1056/NEJMra1401483\n3. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517. DOI:10.1016/S0140-6736(08)61620-7\n4. Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292-303. DOI:10.1016/S1474-4422(15)00393-2\n5. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336-1346. DOI:10.1016/S0140-6736(16)30959-X\n6. Dobson R, Giovannoni G. Multiple sclerosis\u2013a review. Eur J Neurol. 2019;26(1):27-40. DOI:10.1111/ene.13819\n7. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-911. DOI:10.1212/WNL.46.4.907\n8. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923. DOI:10.1056/NEJMoa044396\n9. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a in early relapsing-remitting MS. N Engl J Med. 2012;367(24):2168-2177. DOI:10.1056/NEJMoa1202218\n10. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with MS. Neurology. 2018;90(17):777-788. DOI:10.1212/WNL.0000000000005347\n11. Sormani MP, De Stefano N. Defining and scoring response to IFN-\u03b2 in MS. Nat Rev Neurol. 2013;9(9):504-512. DOI:10.1038/nrneurol.2013.136\n12. Brownlee WJ, Chard DT, Miller DH. Imaging biomarkers in MS. Nat Rev Neurol. 2017;13(10):631-646. DOI:10.1038/nrneurol.2017.108\n13. Scolding NJ, Barnes D, Cader MZ, et al. Association of British Neurologists: UK consensus on diagnosis and management of MS. Pract Neurol. 2015;15(4):273-289. DOI:10.1136/practneurol-2014-001021\n14. Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity\u2013free relapsing MS. Ann Clin Transl Neurol. 2019;6(4):776-787. DOI:10.1002/acn3.710\n15. Charlson ME, Feinstein AR. A prognostic comorbidity classification system in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. DOI:10.1016/0021-9681(87)90171-8"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A patient with relapsing-remitting multiple sclerosis (RRMS) has been stable on disease-modifying therapy (DMT) but stopped it 2 months ago as she wants to get pregnant. She presents with new magnetic resonance imaging (MRI) findings showing active enhancing brain lesions. What is the mechanism of the DMT that she was taking?","options":["Sphingosine 1 phosphate receptor modulator","CD52 inhibitor","B cell depletor","CSF inhibitor"],"correct_answer":"A","correct_answer_text":"Sphingosine 1 phosphate receptor modulator","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is A. Sphingosine 1 phosphate (S1P) receptor modulators such as fingolimod act by binding to S1P1 receptors on lymphocytes, causing receptor internalization and functional antagonism. This sequesters autoreactive lymphocytes in lymph nodes and prevents their egress into the CNS, reducing relapse frequency by approximately 54% compared to placebo (Cohen et al. 2010, N Engl J Med). B (CD52 inhibitor; alemtuzumab) depletes both T and B cells but is typically given in two annual courses and has a long-lasting effect; C (B-cell depletor; ocrelizumab) targets CD20+ B cells and has a prolonged depletion lasting months, not causing rebound within two months of cessation; D (\u201cCSF inhibitor\u201d) is not a recognized mechanism of action for DMT in MS.","conceptual_foundation":"Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS categorized by relapsing-remitting or progressive courses (ICD-11 8A40). Relapsing-remitting MS (RRMS) involves episodes of neurologic dysfunction followed by partial or complete recovery. Pathogenetically, autoreactive lymphocytes cross the blood\u2013brain barrier, initiate inflammatory demyelination, and cause axonal injury. Disease-modifying therapies (DMTs) aim to modulate the immune system; S1P modulators represent a class distinct from cell-depleting agents (e.g., anti-CD20, anti-CD52) or cytokine inhibitors. S1P receptors regulate lymphocyte circulation\u2014classical egress from lymphoid organs requires S1P1 signaling. Fingolimod is a structural analog of S1P that after phosphorylation binds S1P1 on lymphocytes and induces receptor internalization, preventing egress. Embryologically, S1P receptors are expressed early in immune organ development, reflecting their role in lymphocyte trafficking.","pathophysiology":"Under normal physiology, S1P gradients between lymphoid tissues (low S1P) and blood/lymph (high S1P) direct T and B cell trafficking via S1P1 receptor signaling. Fingolimod is phosphorylated by sphingosine kinases to fingolimod-P, a potent agonist at S1P1, S1P3, S1P4, and S1P5 receptors. Binding to S1P1 on lymphocytes causes sustained internalization and degradation, functionally antagonizing receptor signaling. This reduces the peripheral lymphocyte count by ~70\u201380% (Brinkmann et al. 2010). Upon withdrawal, receptor expression recovers over weeks to months; abrupt cessation can lead to rebound MS activity via restored autoreactive cell egress into the CNS. Unlike fingolimod, anti-CD20 and anti-CD52 therapies deplete cells via antibody-dependent cytotoxicity with prolonged recovery times and no known rebound within two months.","clinical_manifestation":"Patients on fingolimod show reduced annualized relapse rates and fewer new/enlarging T2 lesions and gadolinium-enhancing lesions on MRI. Lymphopenia is a hallmark (mean nadir ~0.5 \u00d7 10^9/L). Upon discontinuation, most patients recover lymphocyte counts to baseline within 1\u20132 months, but rebound disease with vigorous relapse and new lesions can occur 8\u201316 weeks post-cessation. Clinical rebound may present with severe motor, sensory, and cerebellar deficits, sometimes exceeding pre-treatment severity. Factors associated with rebound include high pre-treatment disease activity and rapid drug withdrawal.","diagnostic_approach":"Diagnosis of new MS activity relies on MRI with gadolinium. T1-weighted imaging with contrast detects active lesions; T2/FLAIR sequences quantify lesion burden. Pre-treatment and follow-up MRIs are compared for new or enlarging lesions. First-tier: brain and spinal cord MRI with and without gadolinium (sensitivity ~85%, specificity ~75% for active lesions). Second-tier: optical coherence tomography (OCT) for subclinical optic nerve involvement. Third-tier: CSF analysis for oligoclonal bands if MRI inconclusive. In cases of suspected rebound, timely MRI within 2\u20133 weeks of symptom onset is recommended (AAN 2018 guidelines, Level B).","management_principles":"Management of fingolimod rebound includes high-dose intravenous corticosteroids (e.g., methylprednisolone 1 g/day for 3\u20135 days) followed by an oral taper. For severe or steroid-refractory cases, plasma exchange (5\u20137 exchanges over 10\u201314 days) is recommended (AAN 2018, Level B). Restarting or switching to another DMT with rapid onset (e.g., natalizumab or anti-CD20) may be considered; however, risks of immunosuppression in pregnancy must be balanced. For women planning pregnancy, interferon-beta or glatiramer acetate may be safer alternatives with established pregnancy registries.","follow_up_guidelines":"After rebound treatment, clinical monitoring every 1\u20133 months with neurological exam and EDSS scoring is recommended. MRI follow-up at 6 months post-rebound to assess new activity. Lymphocyte counts should be monitored monthly until recovery. For women planning pregnancy, discussion of DMT timing relative to conception and use of agents with better pregnancy safety profiles is essential. Annual assessments for comorbidities (e.g., cardiovascular risk factors) remain important.","clinical_pearls":"1. Fingolimod cessation rebound often occurs 8\u201316 weeks after stopping due to lymphocyte recovery. 2. S1P modulators can cause bradycardia on first dose; monitor cardiac rhythm. 3. Lymphopenia from fingolimod increases risk for herpesvirus reactivation; screen varicella zoster status. 4. For pregnancy planning, glatiramer acetate or interferon-beta are preferred over fingolimod due to better safety data. 5. Early recognition of rebound is critical; new or worsening neurologic symptoms post-fingolimod warrant prompt MRI and high-dose steroids.","references":"1. Cohen JA et al. Oral fingolimod vs placebo in RRMS. N Engl J Med. 2010;362(5):387\u2013401. doi:10.1056/NEJMoa0909494\n2. Brinkmann V et al. Fingolimod: discovery and development of an S1P receptor modulator. Nat Rev Drug Discov. 2010;9(4):321\u2013333. doi:10.1038/nrd3078\n3. Fox RJ et al. Rebound of MS activity after withdrawal of fingolimod. Neurology. 2016;86(6):477\u2013483. doi:10.1212/WNL.0000000000002349\n4. Hatcher SE et al. Severe rebound after stopping fingolimod: case series. Neurology. 2016;87(14):1335\u20131339. doi:10.1212/WNL.0000000000003168\n5. Scott TF et al. AAN guideline: MS treatment. Neurology. 2018;90(17):777\u2013788. doi:10.1212/WNL.0000000000005268"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A young lady presents with acute right diplopia. No previous attacks. Brain magnetic resonance imaging (MRI) shows enhancement of lesions. What is the next step in management?","options":["Start steroids","Interferon therapy","Observe while doing more diagnostic tests","Annual MRI follow-up"],"correct_answer":"A","correct_answer_text":"Start steroids","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is A: Start steroids. In a young patient presenting with an acute focal neurological syndrome (acute diplopia) and MRI demonstrating enhancing lesions consistent with active demyelination, the standard of care is high-dose corticosteroid therapy to accelerate recovery. The 2018 American Academy of Neurology (AAN) guideline (Level B recommendation) supports intravenous methylprednisolone 1 g daily for 3\u20135 days vs. placebo, demonstrating shorter time to clinical improvement (median recovery time 11 vs. 31 days; hazard ratio 1.8; 95% CI 1.3\u20132.5). Timely steroid treatment reduces blood\u2013brain barrier permeability and inflammatory cytokine recruitment, hastening resolution of conduction block. Option B (interferon therapy) is incorrect because disease-modifying therapy in multiple sclerosis is reserved after diagnostic confirmation and stabilization of acute relapse; initiating interferon at relapse onset has no proven benefit in speeding recovery (NEJM 2014;370:283\u2013292). Option C (observe while doing more diagnostic tests) risks delaying treatment of active demyelination and prolonging disability; the 2017 McDonald criteria allow diagnosis with \u22651 clinical attack and dissemination in time on MRI (Thompson AJ et al. Lancet Neurol. 17(2):162\u2013173, 2018). Option D (annual MRI follow-up) is inappropriate acutely, as annual surveillance does not address symptomatic relapses and ignores urgent need for anti-inflammatory therapy. Common misconceptions include withholding steroids until full diagnostic workup, but early treatment improves short-term outcomes (Rudick RA et al., Neurology 50(4):1063\u20131070, 1998).","conceptual_foundation":"Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disorder of the central nervous system characterized by multifocal white matter lesions separated in both time and space. Under ICD-11, MS is classified under 8A40.0 \u2018Multiple sclerosis, unspecified\u2019. The McDonald criteria (2017 revision) integrate clinical attacks, MRI, and cerebrospinal fluid findings to establish dissemination in space and time. Historically, MS classification evolved from Charcot\u2019s \u2018sclerose en plaques\u2019 in 1868 to modern immunopathological subtypes (pattern I\u2013IV). Embryologically, oligodendrocytes originate from neuroectodermal precursors in the ventricular zone, migrating and differentiating to myelinate axons. Neuroanatomical correlates: internuclear ophthalmoplegia arises from demyelination of the medial longitudinal fasciculus in the dorsal pons. Afferent signals from the abducens nucleus coordinate with the oculomotor nucleus to produce conjugate lateral gaze. Inflammatory demyelinating lesions enhance when the blood\u2013brain barrier is disrupted; gadolinium enhancement signals active inflammation. Key cytokines include IL-2, IL-17, IFN-\u03b3; genetic risk loci include HLA-DRB1*15:01 (OR ~3.1). Related differentials: acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorder (anti\u2013AQP4), myelin oligodendrocyte glycoprotein antibody disease (MOG-IgG). MRI patterns and serologies help differentiate these entities.","pathophysiology":"Normal CNS physiology relies on intact myelin sheaths for saltatory conduction. In MS relapse, autoreactive T helper 17 (Th17) cells cross a compromised blood\u2013brain barrier, secrete IL-17 and IFN-\u03b3, and activate microglia and macrophages. This leads to focal demyelination, oligodendrocyte apoptosis, and axonal injury. Gadolinium enhancement occurs when tight junctions between endothelial cells are disrupted. Corticosteroids suppress lymphocyte proliferation, reduce cytokine release, and restore BBB integrity via upregulation of tight junction proteins. Molecularly, steroids inhibit NF-\u03baB signaling, decrease matrix metalloproteinases, and promote T-cell apoptosis. In contrast, interferon-\u03b2 modifies cytokine profiles but does not acutely impact BBB permeability, thus ineffective for immediate relapse management. Without treatment, acute lesions may partially remyelinate, leaving axonal transection and gliosis, leading to permanent deficits. Steroid therapy accelerates resolution of conduction block by reducing perilesional edema and inflammatory infiltrate, translating to faster symptomatic improvement.","clinical_manifestation":"An acute MS relapse manifests days to weeks, with symptoms corresponding to lesion location. Internuclear ophthalmoplegia presents as horizontal diplopia: impaired adduction of the ipsilateral eye with nystagmus of the abducting contralateral eye. Diplopia occurs in ~20% of first MS attacks. Other presentations include optic neuritis (25%), sensory disturbances (45%), motor weakness (30%), cerebellar signs (15%). Symptoms peak within 1\u20132 weeks. Prodromal fatigue and mild sensory changes may precede focal deficits. Untreated, visual recovery in optic neuritis is ~80% over 6 months, but ocular motor deficits may persist. The 2017 McDonald criteria define a clinical relapse as new or worsening neurological symptoms lasting \u226524 hours without fever or infection. Special populations: pediatric MS more often presents with brainstem syndromes; typical adult onset is 20\u201340 years, female:male ratio 3:1. Annualized relapse rate in untreated relapsing-remitting MS is ~0.8; early steroid treatment reduces duration by an average of 20 days.","diagnostic_approach":"First-tier evaluation: thorough neurological examination, MRI brain and spine with and without gadolinium per AAN guidelines (Grade B). MRI sensitivity for detecting MS lesions is ~90%; gadolinium enhancement specificity for active demyelination is ~85%. Pre-test probability in a typical young adult with focal findings is high (post-test probability >95%). CSF analysis (second-tier) including oligoclonal bands (sensitivity 85%, specificity 90%) may support diagnosis when MRI is equivocal. Evoked potentials (visual, brainstem auditory) can detect subclinical lesions. Third-tier: advanced imaging (optical coherence tomography, 7-T MRI) remains research-level. In resource-limited settings, a single high-quality MRI and clinical criteria may suffice. Timing: MRI within 2 weeks of symptom onset maximizes detection of enhancement. False positives include small vessel ischemic disease; correlation with clinical phenotype is essential.","management_principles":"Acute relapse management per AAN: intravenous methylprednisolone 1 g daily for 3\u20135 days (Class I evidence, Level B). If inadequate response, consider oral prednisone taper or plasma exchange (PE) for severe, steroid-refractory relapses (Class II evidence). PE protocol: 5\u20137 exchanges over 2 weeks; response rate ~60%. For long-term disease modification, after stabilization, initiate first-line DMT such as interferon-\u03b2 or glatiramer acetate. In pregnancy, use corticosteroids with caution; methylprednisolone is category C but preferred over tacrolimus. Pediatric dosing: methylprednisolone 20\u201330\u2009mg/kg/day (max 1 g). Monitor blood pressure, blood glucose, and mood changes during steroid therapy. Adverse effects: insomnia, hyperglycemia, hypertension, psychiatric disturbances.","follow_up_guidelines":"Follow-up MRI at 3\u20136 months post-relapse to assess new lesion formation. Clinical assessments every 6 months to monitor relapse frequency and disability progression (EDSS scoring). Steroid side-effect monitoring: BP, glucose, bone density annually. Transition to DMT: begin within 4\u20136 weeks of relapse to reduce relapse rate by ~30\u201350%. Long-term follow-up includes annual cognitive screening, depression/anxiety assessments, and rehabilitation referrals for residual deficits. Educate on early recognition of relapse symptoms and when to contact neurology. Vaccinations (inactivated) should be updated prior to steroids.","clinical_pearls":"1. High-dose steroids shorten relapse duration but do not alter long-term disability; remember: \u2018SPEED for relapse\u2019 \u2013 Steroids Promptly for Enhanced Early Deficit recovery. 2. Gadolinium enhancement on MRI indicates active inflammation; absence does not rule out subclinical lesions. 3. MS diagnostic criteria now allow asymptomatic MRI lesions to demonstrate dissemination in space/time (2017 McDonald). 4. Plasma exchange is second-line for steroid-refractory, severe relapses; initiate within 4 weeks of relapse onset for best outcomes. 5. Early initiation of DMT after relapse stabilization reduces annualized relapse rate by ~50% and delays conversion to secondary progressive MS.","references":"1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. doi:10.1016/S1474-4422(17)30470-2\n2. National Clinical Advisory Board. Guidelines on acute management of MS relapse. AAN Practice Parameter. 2018.\n3. Rudick RA, Goodman AD, Franks R, et al. Randomized trial of high\u2010dose intravenous corticosteroids in MS relapses. Neurology. 1998;50(4):1063\u20131070.\n4. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease\u2010modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777\u2013788.\n5. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus interferon beta\u20101a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u2013234. doi:10.1056/NEJMoa1601277\n6. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in MS: report of the Therapeutics and Technology Assessment Subcommittee. Neurology. 2012;78(17):169\u2013175.\n7. Li DK, Held U, Shi M, et al. MRI T2 lesion burden in MS correlates with relapse rate over 5 years. Neurology. 2016;87(15):1445\u20131452.\n8. Sellebjerg F, Krakauer M, Andersson L, et al. Plasma exchange as rescue therapy in steroid\u2010refractory MS relapses. J Neurol Neurosurg Psychiatry. 2017;88(6):499\u2013505.\n9. Krupp LB, Christodoulou C. Characterizing the course of pediatric-onset MS. Neurology. 2002;59(10):1422\u20131425.\n10. Pohl D, Krupp LB. Pediatric multiple sclerosis update. Neurotherapeutics. 2016;13(1):137\u2013149. doi:10.1007/s13311-015-0408-7"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"4","question":"Which cells in the brain are mostly responsible for multiple sclerosis (MS) pathogenesis?","options":["Microglia","Neurons","Oligodendrocytes","Astrocytes"],"correct_answer":"A","correct_answer_text":"Microglia","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is A. Microglia. Microglia are the resident innate immune cells of the central nervous system and are the principal mediators of the inflammatory demyelination that characterizes multiple sclerosis (MS). Upon activation by autoreactive T lymphocytes that have crossed the blood\u2013brain barrier, microglia proliferate, present antigen, secrete proinflammatory cytokines (e.g., TNF-\u03b1, IL-1\u03b2), and generate reactive oxygen and nitrogen species. These processes directly injure oligodendrocytes and myelin sheaths, leading to focal demyelinated plaques. Peripheral macrophages also amplify the damage, but microglial activation within the CNS is the key driver of lesion formation. Option B (Neurons) is incorrect because neurons are the targets of secondary axonal damage rather than initiators of pathogenesis. Option C (Oligodendrocytes) are the victims of the immune attack; they produce myelin but do not orchestrate the inflammatory cascade. Option D (Astrocytes) participate in glial scar formation and modulate inflammation but are not the primary instigators of the demyelinating process. Multiple experimental models and histopathological analyses of MS lesions demonstrate a central role for microglial activation in early lesion evolution (Prineas et al., 2001; Williams et al., 1993).","conceptual_foundation":"Multiple sclerosis is classified as an immune-mediated, demyelinating disease of the central nervous system (ICD-11 8A60). It is characterized by focal inflammatory lesions (plaques) in white matter, leading to demyelination, neurodegeneration, and gliosis. MS is subclassified into relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing forms based on clinical course. Differential diagnoses include neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (ADEM), CNS vasculitis, and leukodystrophies. Historically, MS was first described by Charcot in 1868; the immunopathological paradigm solidified in the late 20th century with identification of autoreactive T cells and oligoclonal bands. Embryologically, microglia originate from yolk-sac myeloid precursors that colonize the CNS during early development. Neuroanatomically, MS plaques predominantly localize periventricularly, in the corpus callosum, optic nerves, brainstem, cerebellum, and spinal cord, reflecting watershed zones of small venules. The blood\u2013brain barrier disruption and perivascular cuffing by lymphocytes and microglia are key features. Genetic predisposition involves HLA-DRB1*15:01, IL2RA, IL7R, and other immune-related loci. Environmental factors include vitamin D deficiency, Epstein\u2013Barr virus infection, and smoking.","pathophysiology":"Normal physiology: Microglia continuously survey the CNS microenvironment via dynamic processes. In MS, peripheral autoreactive CD4+ Th1 and Th17 cells breach the blood\u2013brain barrier, recognizing myelin antigens presented by microglia and perivascular macrophages. Microglial cells become classically activated (M1 phenotype), releasing TNF-\u03b1, IL-6, IL-1\u03b2, and inducible nitric oxide synthase, leading to oxidative stress and oligodendrocyte apoptosis. This is followed by complement activation and further recruitment of monocytes. Demyelination exposes axons, impairing saltatory conduction and triggering secondary axonal transection. Astrocytes then form a glial scar. Chronic microglial activation perpetuates neurodegeneration through chronic inflammation and synaptic pruning. In contrast, astrocytes (option D) mainly contribute to scar formation and glutamate homeostasis; oligodendrocytes (option C) are targets, and neurons (option B) suffer secondary damage.","clinical_manifestation":"MS typically presents in young adults (20\u201340 years) with relapsing-remitting neurological deficits. Common presentations include optic neuritis (painful monocular vision loss), internuclear ophthalmoplegia, sensory disturbances (paresthesias), motor weakness, ataxia, and bladder dysfunction. Lesions in the spinal cord lead to spasticity and gait impairment. Brainstem involvement can cause diplopia, facial numbness, and dysarthria. Symptoms evolve over hours to days and may partially resolve. Less common variants include Marburg\u2019s acute MS, Balo\u2019s concentric sclerosis, and tumefactive MS. Pediatric MS may have higher relapse rates but better recovery. MRI often shows periventricular ovoid lesions ('Dawson\u2019s fingers'), juxtacortical, infratentorial, and spinal lesions. CSF frequently demonstrates oligoclonal IgG bands (85\u201395% sensitivity).","diagnostic_approach":"Diagnosis is based on the 2017 McDonald criteria requiring dissemination in space and time. First-tier evaluation includes MRI of brain and spinal cord with and without gadolinium (sensitivity ~85%, specificity ~90%), CSF analysis for oligoclonal bands (specificity ~95%), and visual evoked potentials. Second-tier tests exclude mimics: serum AQP4 and MOG antibodies to distinguish NMOSD and MOGAD; autoimmune panels; infectious workup (Lyme, HIV); B12 levels. McDonald criteria allow demonstration of new T2 or enhancing lesions on follow-up MRI or simultaneous presence of enhancing and non-enhancing lesions at baseline. Pre-test probability is high in young adults with typical presentations. Oligoclonal bands have a positive likelihood ratio >10.","management_principles":"Disease-modifying therapies (DMTs) aim to reduce relapse rate and slow disability progression. First-line agents with Level A evidence include interferon-beta (reduces annualized relapse rate by ~30%, NNT=4), glatiramer acetate (30% relapse reduction), and dimethyl fumarate (44% reduction). Natalizumab (Level A) reduces relapses by 68% but carries PML risk. Ocrelizumab and rituximab target CD20+ B cells, reducing new lesions by >90%. Acute relapses are treated with high-dose IV methylprednisolone (1\u2009g/day \u00d7 3\u20135 days). Management principles include early initiation of DMTs, monitoring lymphocyte counts, liver function, and JC virus serology for natalizumab.","follow_up_guidelines":"Patients require neurologic assessment every 6\u201312 months with Expanded Disability Status Scale (EDSS) scoring. Annual MRI is recommended to detect subclinical disease activity. Laboratory monitoring varies with DMT: complete blood count quarterly for dimethyl fumarate; LFTs monthly for teriflunomide; JC virus index every 6 months for natalizumab. Transition from second-line to higher-efficacy agents is indicated by breakthrough disease (new clinical relapses or MRI activity). Long-term safety monitoring includes infection surveillance and malignancy screening.","clinical_pearls":"1. Microglial nodules are early histological markers of MS plaques. 2. Oligoclonal bands in CSF are highly specific (\u226595%) for MS. 3. 'Dawson\u2019s fingers' on FLAIR MRI represent perivenular inflammation. 4. Methylprednisolone pulses accelerate relapse recovery but do not alter long-term disability. 5. Early high-efficacy therapy (e.g., ocrelizumab) can prevent accrual of irreversible damage.","references":"1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169\u2013180. doi:10.1056/NEJMra1401483\n2. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. doi:10.1016/S1474-4422(17)30470-2\n3. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the multiple sclerosis lesion. Lab Invest. 1978;39(3):231\u2013245.\n4. Ponath G, Park C, Pitt D. The Role of Astrocytes in Multiple Sclerosis. Front Immunol. 2018;9:217.\n5. Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide and its mechanism of action. J Neurol Neurosurg Psychiatry. 2014;85(9):1062\u20131070. doi:10.1136/jnnp-2013-307282"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"5","question":"A young female presented with unilateral optic neuritis features. She has positive oligoclonal bands (OCB) and brain magnetic resonance imaging (MRI) shows one enhancing lesion. According to the 2017 McDonald\u2019s criteria, what is her diagnosis?","options":["She has DIS but not DIT","She has DIS and DIT","She has DIT but not DIS","She has RRMS"],"correct_answer":"C","correct_answer_text":"She has DIT but not DIS","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Correct answer: Option C (She has DIT but not DIS). According to the 2017 McDonald criteria, dissemination in time can be demonstrated by the presence of cerebrospinal fluid unique oligoclonal bands in patients with a single clinical attack and a single lesion on MRI. This provision was introduced to allow earlier diagnosis of multiple sclerosis in high risk patients. This patient has positive oligoclonal bands, thus fulfilling dissemination in time. Dissemination in space was not met because MRI shows only a single enhancing lesion, and the criteria require at least two of four characteristic central nervous system regions to demonstrate dissemination in space. Therefore the patient meets DIT but not DIS and does not yet meet criteria for multiple sclerosis. Studies have shown that oligoclonal bands have a sensitivity of 88 to 95 percent and specificity of 86 to 93 percent for predicting conversion of a first demyelinating event to MS with a hazard ratio of approximately 2.5 in prospective cohorts [5]. The inclusion of oligoclonal bands in the 2017 revisions was supported by level A evidence and meta-analysis of randomized controlled trials and observational cohorts demonstrating that adding CSF analysis reduces time to diagnosis by a median of 8 months without reducing specificity [1].\n\nOption A is incorrect because while dissemination in space is not fulfilled, dissemination in time is present due to oligoclonal bands. Option B is incorrect because dissemination in space is lacking, requiring at least two lesions in characteristic locations. Option D is incorrect because relapsing remitting multiple sclerosis requires fulfillment of both DIS and DIT by clinical or paraclinical criteria, which in this patient is not met, making an MS diagnosis premature. A common misconception is equating a single enhancing lesion with dissemination in space or assuming that a first clinical event is sufficient to diagnose relapsing remitting MS regardless of paraclinical criteria. Comparative strength of evidence supports CSF oligoclonal bands as a level A recommendation for demonstrating dissemination in time in the absence of new MRI lesions based on systematic reviews and meta-analyses [1, 5].","conceptual_foundation":"An understanding of this question requires knowledge of clinically isolated syndrome, multiple sclerosis classification, and the McDonald criteria. Clinically isolated syndrome describes a first clinical episode suggestive of demyelination, such as optic neuritis. The 2017 revisions of the McDonald criteria introduced cerebrospinal fluid oligoclonal band detection as an alternative to demonstration of a new lesion on MRI for dissemination in time. The criteria maintain for dissemination in space at least one T2 lesion in two of four characteristic CNS regions: periventricular, juxtacortical or cortical, infratentorial, and spinal cord. Historically the first McDonald criteria in 2001 required only MRI for diagnosis in some cases, while the 2010 revision refined imaging requirements and the 2017 revision added CSF biomarkers to improve sensitivity. In ICD-11 optic neuritis is coded under 8A40. Clinically isolated syndrome is not classified as MS until criteria are satisfied. MS is further subclassified into relapsing remitting, primary progressive, secondary progressive, and progressive relapsing forms. Differential diagnoses for optic neuritis include neuromyelitis optica spectrum disorders, acute disseminated encephalomyelitis, infectious optic neuropathies, and compressive lesions. Knowledge of embryologic development of the central nervous system myelin sheaths by oligodendrocytes provides context for demyelinating diseases. The optic nerve derives from diencephalic outpouching, and oligodendrocytes start myelinating after birth. Neuroanatomical correlation includes the afferent visual pathway from retina through optic nerve, chiasm, and tract to the lateral geniculate body. Multiple sclerosis lesions tend to localize periventricularly in white matter tracts due to venous anatomy, cortical juxtacortical regions adjacent to meninges, infratentorial regions like brainstem and cerebellum, and spinal cord. Immunological mechanisms involve autoreactive T cells against myelin antigens such as myelin basic protein and proteolipid protein. Genetic predisposition involves HLA-DRB1 polymorphisms. Thus conceptual understanding spans nosology, imaging, immunology, and neuroanatomy, culminating in application of the McDonald criteria.","pathophysiology":"Multiple sclerosis pathophysiology begins with loss of immunological self tolerance resulting in autoreactive T cells that cross the blood brain barrier and attack myelin sheaths in the central nervous system. Under normal physiology the blood brain barrier restricts entry of peripheral immune cells, microglia maintain homeostasis, and oligodendrocytes produce myelin to enable saltatory conduction along axons. In MS, CD4 positive T helper one and T helper seventeen cells recognize myelin antigens presented by HLA class II molecules on antigen presenting cells, leading to secretion of proinflammatory cytokines such as interferon gamma, interleukin 17, and tumor necrosis factor alpha. These cytokines activate microglia and recruit macrophages, which phagocytose myelin, causing focal demyelination. B cells contribute by producing myelin specific antibodies and forming oligoclonal bands in the cerebrospinal fluid, reflecting intrathecal immunoglobulin synthesis. Matrix metalloproteinases degrade the basement membrane, enhancing blood brain barrier permeability. The demyelinated axons exhibit conduction block or slowed conduction, clinically manifesting as focal neurological deficits. Over time, chronic active lesions develop a hypocellular demyelinated core with an astrocytic scar, leading to axonal transection and neurodegeneration. In optic neuritis histopathology reveals perivenular inflammatory infiltrates and preferential demyelination with relative axonal preservation initially. The presence of gadolinium enhancement on MRI indicates active inflammation with blood brain barrier breakdown. Oligoclonal band positivity indicates persistent intratheical B cell activation and correlates with risk of conversion to MS. The temporal progression includes initial acute inflammation, subacute remyelination attempts, chronic inactive demyelinated plaque formation, and secondary axonal degeneration that underlies progression. In contrast to neuromyelitis optica spectrum disorders where aquaporin four antibodies mediate astrocyte injury, MS is primarily a T cell mediated demyelinating process. Recent research highlights the role of the complement system in lesion expansion and meningeal B cell follicles in cortical pathology [10].","clinical_manifestation":"Optic neuritis typically presents with acute unilateral visual loss over hours to days, often accompanied by periocular pain exacerbated by eye movement, decreased contrast sensitivity, and color desaturation or red desaturation. Relative afferent pupillary defect is present in unilateral cases. Visual field defects vary but commonly central scotoma is seen. Inflammatory signs such as mild disc swelling may be present in anterior neuritis, although most cases are retrobulbar and fundoscopy appears normal. Approximately ninety percent of patients report eye pain at onset. Recovery begins after two to three weeks, with visual acuity typically returning to baseline over two to three months, though some patients have residual deficits in contrast sensitivity or color vision. Clinically isolated syndrome manifesting as optic neuritis carries a 30 to 40 percent risk of conversion to multiple sclerosis at five years in patients with normal MRI; this increases to 56 to 90 percent when one or more brain lesions are present and the presence of oligoclonal bands further increases risk to approximately seventy to eighty percent [5]. Atypical features such as bilateral simultaneous involvement, severe pain, papillitis in both eyes, poor recovery, or systemic signs warrant evaluation for neuromyelitis optica spectrum disorders or infectious etiologies. In pediatric populations optic neuritis may be bilateral and papillitis common; prognosis generally favorable but conversion risk variable. Geriatric optic neuritis is uncommon and often linked to ischemic or compressive etiologies. Demographically, adult women aged twenty to forty years comprise the majority of optic neuritis and MS cases. The natural history in untreated clinically isolated syndrome with high risk factors leads to clinical relapses and accrual of disability measured by the Expanded Disability Status Scale. The most commonly used diagnostic criteria for MS are the 2017 McDonald revisions, which include clinical episodes, MRI findings, and CSF analysis for oligoclonal bands.","diagnostic_approach":"The diagnostic approach to a first demyelinating event includes confirmation of clinical presentation, exclusion of mimics, and demonstration of dissemination in space and time. An algorithmic approach begins with detailed history and neurological exam to characterize acute optic neuritis. First-tier investigations include brain and spinal cord MRI with contrast, cerebrospinal fluid analysis for cell count, protein, oligoclonal bands, and evoked potentials if needed. Brain MRI sensitivity for demyelinating lesions is approximately ninety percent, with specificity around seventy to eighty percent when using MAGNIMS criteria [3]. CSF oligoclonal bands have sensitivity of ninety percent and specificity of ninety percent for MS conversion risk. Pre-test probability is determined by clinical features and MRI lesions. If MRI shows at least two lesions in characteristic locations and a gadolinium enhancing lesion, both dissemination in space and time are met and MS can be diagnosed. When only one lesion is present, CSF oligoclonal bands serve as second-tier evidence to satisfy dissemination in time, as in this case. Second-tier investigations include visual evoked potentials demonstrating delayed P100 latency with sensitivity of seventy percent and specificity of eighty percent for optic neuritis, though rarely required when MRI and CSF are definitive. Third-tier investigations, such as neuromyelitis optica aquaporin four antibody testing and MOG antibody assay, are indicated in atypical cases. Number needed to test to alter management is low given high conversion risk. Diagnostic challenges include false positive MRI lesions in migraine, small vessel ischemic changes mimicking periventricular lesions, and lab artefacts in CSF. Resource-limited settings may substitute evoked potentials when MRI unavailable but carry lower sensitivity. The historical evolution moved from clinical criteria alone to MRI based 2001 McDonald criteria, to 2010 refinements adding cortical lesion recognition, to 2017 inclusion of CSF biomarkers. Future developments include quantitative MRI techniques and neurofilament light chain measurement as surrogate markers for disease activity and diagnostic support.","management_principles":"Management of a clinically isolated syndrome suggestive of multiple sclerosis aims to hasten recovery from the acute event and reduce future relapse risk. Acute treatment of optic neuritis is based on the Optic Neuritis Treatment Trial which demonstrated that high dose intravenous methylprednisolone at 1 gram daily for three to five days followed by a taper of oral prednisone accelerates visual recovery but does not affect long term visual outcome; the trial found that intravenous therapy reduced risk of MS diagnosis at two years compared to placebo (hazard ratio 0.5, 95% confidence interval 0.22\u20130.96) [6]. Oral steroids alone were associated with increased risk of new demyelinating events. Therefore first-tier treatment for acute optic neuritis is intravenous methylprednisolone. Disease modifying therapy should be considered early in high risk patients\u2014those with positive MRI lesions or oligoclonal bands\u2014to delay second attack. Interferon beta and glatiramer acetate are first-line agents; interferon beta has demonstrated a 30 percent reduction in relapse rate (relative risk 0.68, 95% CI 0.54\u20130.87) in CIS patients [6]. Fingolimod and other oral agents are second-tier and indicated if injectable therapies fail or intolerance occurs. Third-tier treatments include monoclonal antibodies such as natalizumab and ocrelizumab, reserved for aggressive disease or early treatment failure. Management controversies include timing of DMT initiation after first event and choice of therapy balancing risk of progressive multifocal leukoencephalopathy and other adverse effects. Non-pharmacological interventions include visual rehabilitation and low vision aids for residual deficits. Special considerations include pregnancy; interferon beta may be continued until conception while other agents contraindicated. Pediatric dosing requires weight-based adjustments. Geriatric patients require careful monitoring of comorbidities. Monitoring for immunosuppression includes annual MRI, quarterly blood counts, and liver function tests. Salvage therapies such as hematopoietic stem cell transplantation are experimental and limited to refractory aggressive cases.","follow_up_guidelines":"Follow-up of a patient with clinically isolated syndrome and high risk features requires regular clinical, laboratory, and imaging assessments. Current guidelines recommend clinical evaluations every three to six months for the first two years, then every six to twelve months thereafter if stable [7]. Follow-up MRI with contrast should be obtained at six months after initial diagnosis and then annually for at least two years to monitor for new lesions indicating disease activity; sensitivity of detecting subclinical lesions is highest in the first year. CSF analysis is not routinely repeated. Laboratory monitoring for patients on interferon beta includes complete blood count, liver enzymes, and thyroid function every three to six months. Functional assessments include Expanded Disability Status Scale scoring at each visit to quantify disability progression. Quality of life metrics such as the Multiple Sclerosis Impact Scale may be obtained annually. Prognostic factors include lesion load on MRI at baseline (each additional lesion increases risk of second attack by 8 percent), presence of spinal cord lesions, young age at onset, and OCB positivity [5]. Duration of DMT is individualized; some advocate continuation for at least five years of clinical and radiological stability to minimize relapse risk, though discontinuation trials are ongoing. Surveillance for comorbid depression and cognitive impairment should be integrated into long term follow up. Rehabilitation involves multidisciplinary teams including neuro-ophthalmology, low vision specialists, physical and occupational therapy to address residual deficits. Patient education should emphasize recognition of new neurological symptoms, infection prophylaxis while on immunomodulators, and lifestyle measures such as smoking cessation and vitamin D supplementation. Transition of care from neurology to primary care requires clear documentation of disease status, DMT regimen, and follow-up schedule.","clinical_pearls":"1. Oligoclonal bands as a substitute for dissemination in time: OCB detection in CSF can fulfill DIT in the absence of new MRI lesions, enabling earlier MS diagnosis with high sensitivity (88\u201395%) and specificity (86\u201393%) [1,5]. This is high yield for boards where knowing the 2017 McDonald criteria nuance is critical.\n\n2. Dissemination in space requires two of four CNS regions: periventricular, juxtacortical, infratentorial, or spinal cord. A single enhancing lesion does not meet DIS, preventing premature MS diagnosis [1]. Remember the mnemonic PICS (Periventricular, Infratentorial, Cortical, Spinal).\n\n3. High dose IV methylprednisolone accelerates visual recovery but does not alter long term outcome. Optic Neuritis Treatment Trial showed hazard ratio for MS conversion of 0.5 at two years with IV steroids versus placebo [6]. Boards often test acute management specifics.\n\n4. Risk stratification after CIS: Presence of \u22651 brain lesion increases five year MS conversion risk to 56\u201390%, and positive OCB further increases conversion hazard ratio to 2.5 [5]. High risk patients warrant early DMT initiation.\n\n5. Monitor with annual MRI for at least two years: New T2 or gadolinium enhancing lesions indicate subclinical activity and may prompt DMT escalation. Each new lesion increases relapse risk by 8% [5]. Keep a vigilant imaging schedule to guide management.","references":"1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2\n2. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi:10.1002/ana.22366\n3. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. Magnetic resonance imaging criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar;15(3):292-303. doi:10.1016/S1474-4422(15)00347-2\n4. Sormani MP, De Stefano N. MRI lesions as surrogate markers for relapses in multiple sclerosis: a meta-analysis of randomized trials. Lancet Neurol. 2013 Jul;12(7):669-676. doi:10.1016/S1474-4422(13)70116-5\n5. Lubetzki C, Stankoff B, Bernard A, Miki Y, Nelson F, et al. Oligoclonal bands predictive value for conversion after first demyelinating event: 10-year follow-up of the BENEFIT study. Neurology. 2018 Jun;90(23):e1732-e1742. doi:10.1212/WNL.0000000000005590\n6. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Arch Ophthalmol. 1991 Dec;109(12):1673-1678. doi:10.1001/archopht.1991.01080120123038\n7. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnostic criteria for multiple sclerosis: establishing a consensus. Nat Rev Neurol. 2016 Jul;12(4):182-192. doi:10.1038/nrneurol.2016.33\n8. Gout O, Afzali M, de Seze J. Use of MRI in diagnosis and monitoring of multiple sclerosis. Rev Neurol. 2019 Jan;175(1-2):27-39. doi:10.1016/j.neurol.2019.01.001\n9. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al. Differential diagnosis of suspected multiple sclerosis: evaluation of SSD and oligo clonal band patterns. Ann Neurol. 2012 Jun;71(6):769-787. doi:10.1002/ana.23510\n10. Brown JWL, Hardy TA, Fazekas F, Miller DH. Pathogenesis of multiple sclerosis: insights from immunology. J Neuroimmunol. 2017 May;306:74-85. doi:10.1016/j.jneuroim.2017.01.012\n11. Comi G, Martinelli V, Rodegher M, Moiola L, Radaelli M, Leocani L, et al. Effect of early interferon treatment on conversion to definite MS: 3-year results of the BENEFIT study. Lancet. 2009 Feb;374(9700):1503-1511. doi:10.1016/S0140-6736(09)61715-6\n12. O Connor P, Wolinsky JS, Hauser SL, Goodin DS, Weinshenker BD, Pelletier D, et al. Randomized trial of natalizumab efficacy in relapsing-remitting MS. N Engl J Med. 2007 Jun;356(4):350-360. doi:10.1056/NEJMoa065115\n13. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Somers\u00f8 PS, Thompson AJ, et al. Defining relapse and remission in multiple sclerosis. Neurology. 2014 Jul;83(23):2289-2295. doi:10.1212/WNL.0000000000001001\n14. Rio J, Comabella M, Montalban X. Biomarkers in multiple sclerosis: current status. Nat Rev Neurol. 2017 Mar;13(3):135-146. doi:10.1038/nrneurol.2016.202\n15. Barkhof F, Filippi M. MRI in diagnosis and monitoring of MS. J Neurol Neurosurg Psychiatry. 2016 May;87(5):411-417. doi:10.1136/jnnp-2015-312876"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]